DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting

World News: . []

DBV Technologies Euronext DBV - ISIN FR0010417345 - Nasdaq Stock Market: DBVT a clinical-stage biopharmaceutical company today announced that additional analyses from clinical trials of Viaskin Peanut will be presented at the 2018 American Col lege of...

More news and information about DBV Technologies S.A.

Published By:

Globe Newswire: 06:32 GMT Friday 9th November 2018

Published: .

Search for other references to "technologies" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us